Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 24K
5: R1 Cover Page HTML 45K
8: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- exel-20220411_htm XML 21K
7: EXCEL IDEA Workbook of Financial Reports XLSX 6K
3: EX-101.LAB XBRL Labels -- exel-20220411_lab XML 67K
4: EX-101.PRE XBRL Presentations -- exel-20220411_pre XML 33K
2: EX-101.SCH XBRL Schema -- exel-20220411 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 16K
10: ZIP XBRL Zipped Folder -- 0000939767-22-000046-xbrl Zip 79K
(Address of principal executive offices) (Zip Code)
(i650)
i837-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i☐Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon Stock $.001 Par Value per Share
iEXEL
iThe
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth companyi☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 11, 2022, Charles Cohen, Ph.D.
notified Exelixis, Inc. (“Exelixis”) of his decision not to stand for re-election to the Board of Directors of Exelixis (the “Board”) at the 2022 annual meeting of stockholders of Exelixis (the “Annual Meeting”) and resign from the Board effective as of the Annual Meeting. Dr. Cohen indicated that his decision not to stand for re-election was not a result of any disagreement with Exelixis on any matter relating to Exelixis’ operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
